For colorectal cancer, current US Preventive Services Task Force guidelines recommend screening beginning at age 45 for average-risk individuals, using colonoscopy, stool-based tests, or other approved methods
Patients with kidney disease, heart failure, or other conditions requiring fluid restriction should follow their healthcare provider's guidance Distribution throughout the day : Spreading fiber across meals rather than concentrating intake at one time Individual tolerance : Some patients may temporarily require slightly lower fiber intake during initial treatment phases Patients experiencing persistent constipation despite adequate fiber and hydration should consult their healthcare provider, as additional interventions such as polyethylene glycol (PEG) or other osmotic laxatives may be appropriate per American Gastroenterological Association guidelines
I feel like myself again. Easy to use website with a streamlined process product delivered straight to my door
Competitive Position Eli Lilly Market Cap: ~$885-930B 2025 Rev Growth: +40-50% Forward P/E: ~31 Positioning: Market leader, oral GLP-1 coming Novo Nordisk Market Cap: ~$204-215B 2025 Rev Growth: +30% Forward P/E: ~12 Positioning: Struggling with competition, stock down 60% from peak Pfizer Market Cap: ~$160B 2025 Rev Growth: Declining Forward P/E: ~12 Positioning: Lost Metsera bid to competition Key Advantages: Tirzepatide (Mounjaro/Zepbound) consistently outperforms Novo's semaglutide (Ozempic/Wegovy) in head-to-head trials First-mover advantage with oral GLP-1 (orforglipron) Manufacturing scale-up: $12.5B+ invested in new facilities (Virginia, Texas, Puerto Rico) Direct-to-consumer platform (LillyDirect) creating pricing flexibility Valuation & Price Targets Current Price: ~$990 Market Cap: ~$885-930B Valuation Framework 2025 Est

Most significantly, its patent in China is set to expire in 2026, which means that the entry of generics could make China the largest market for semaglutide medications